Vascular Disruptive Agents for the Treatment of Cancer

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology, Specialties, Oncology
Cover of the book Vascular Disruptive Agents for the Treatment of Cancer by , Springer New York
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781441966094
Publisher: Springer New York Publication: September 2, 2010
Imprint: Springer Language: English
Author:
ISBN: 9781441966094
Publisher: Springer New York
Publication: September 2, 2010
Imprint: Springer
Language: English

Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis – vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005).

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Angiogenesis (formation of new vessels from pre-existing ones) is a crucial early event in the process of tumor development. New vessels supply the tumor with nutrients that are needed for further local growth and enable distant metastases (Folkman 1995). Judah Folkman (1971) highlighted the potential therapeutic imp- cations of tumor angiogenesis. He hypothesized that if tumor angiogenesis is inhibited, then tumor growth and metastasis will be impaired greatly or even impossible. The subsequent quest for endogenous and exogenous inhibitors of angiogenesis has yielded a variety of promising therapeutic agents that block one or more angiogenic pathways, a few of which have been approved by the FDA (e. g. , bevacizumab, sorafenib, sunitinib) for use as single agents or in combination with chemotherapy in specific populations of cancer patients (Sessa et al. 2008). There has also been a dramatic expansion in the exploration of novel anti-angiogenic agents pre-clinically and in clinical trials (Ferrara 2002). Some of the most promising data comes from the development of agents that inhibit one of the key growth factors involved in tumor angiogenesis – vascular endothelial growth factor (VEGF) (Ferrara et al. 2003). Bevacizumab is a monoclonal antibody against VEGF that was the first an- angiogenic agent that improved significantly the overall survival of patients with colorectal and non-squamous non-small cell lung cancer (Ferrara et al. 2005). Various agents that target tumor angiogenesis are currently under investigation in different cancer types in many clinical trials (Ferrara and Kerbel 2005).

More books from Springer New York

Cover of the book Current Ornithology Volume 17 by
Cover of the book Periprosthetic Joint Infection of the Hip and Knee by
Cover of the book Genomic Elements in Health, Disease and Evolution by
Cover of the book Feedback Strategies for Wireless Communication by
Cover of the book Primary Care Procedures in Women's Health by
Cover of the book The Impacts of Biofuels on the Economy, Environment, and Poverty by
Cover of the book Globalization and Families by
Cover of the book Knee Arthroscopy by
Cover of the book Modern Dermatologic Radiation Therapy by
Cover of the book Policy Initiatives Towards the Third Sector in International Perspective by
Cover of the book Topics in Modal Analysis II, Volume 6 by
Cover of the book A New Unified Theory of Psychology by
Cover of the book Ultrasonography of Muscles and Tendons by
Cover of the book Next Generation Microchannel Heat Exchangers by
Cover of the book Adaptive and Maladaptive Aspects of Developmental Stress by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy